Since age-dependent deposition of Ab-amyloid has been reported in the Microcebus murinus, we posited that this animal could as well be a model of age-related synucleinopathy. We characterized the distribution of Ab-amyloid, a-synuclein and two of its modified forms in the brain of Microcebus murinus aged from 1.5 to 10 years. Intracytoplasmic a-synuclein aggregates were observed only in aged animals in different brain regions, which were also phospho-Ser129 and nitrated a-synuclein immunoreactive. Age-dependent a-synuclein aggregation occurs spontaneously in mouse lemur primates. Microcebus murinus may provide a model to study age-associated a-synucleinopathy and for testing putative therapeutic interventions for both Alzheimer's and Parkinson's diseases.
A nimal models are an essential tool for basic pathophysiological research, age-related research as well as drug development and compound testing in neurodegenerative diseases [1] [2] [3] . So far, most of animal studies on neurodegenerative disorders are based on transgenic mice or rats. Although very useful to unravel cellular mechanisms associated to neuronal cell death during the time course of the disease, no mammalian model recapitulates the full spectrum required age-dependent neurodegeneration, especially in Parkinson disease (PD) 4, 5 . The aggregation-prone protein, a-synuclein, has been implicated in various neurodegenerative disorders by participating in abnormal protein depositions, such as PD, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). The absence of adequate in vivo experimental models of synucleinopathy has severe repercussions for therapeutic intervention success 5 . Natural or ecological models would be an alternative to model pathological accumulation of a-synuclein. Of interest, among primate models, Microcebus murinus might be a very good candidate to study age-associated synucleinopathy 6, 7 . The Microcebus murinus, a small lemurian primate, also referred to as the mouse lemur, has been described as a useful primate model for human cerebral aging and Alzheimer disease 8 . In mouse lemurs, histological studies have shown cerebral morphological and neuropathological alterations associated to ageing, including abundant Ab amyloid plaques, Tau pathology, and atrophy of brain areas such as the cortex, the hippocampus, the thalamus and hypothalamus, the basal ganglia and the cerebellum [9] [10] [11] [12] . In addition, as in humans, magnetic resonance imaging has corroborated age-associated cerebral atrophy and iron accumulation 13, 14 . Based on these studies, we assessed the occurrence of spontaneous a-synuclein accumulation in the mouse lemur brain at different ages. Thus, the present study focuses on Microcebus murinus as a potential model for the study of age-associated synucleinopathy.
Results
We characterized the regional distribution of immunopositivity for misfolded proteins implicated in neurodegenerative diseases, such as Ab deposits and a-synuclein aggregates (Fig. 1A-B) . Intracytoplasmic a-synuclein aggregates were observed only in old animals in the anterior olfactory nucleus, cortex, and regions implicated in PD, such as the substantia nigra pars compacta (SNpc) and the striatum (Fig. 1D-F-H) and not in young individuals (Fig. 1C-E-G ). An antibody that specifically recognizes phospho-Ser129 was used to determine whether neuronal cell bodies in the mouse lemur contain this modified form of a-synuclein and whether asynuclein phosphorylation is enhanced by aging. Phospho-Ser129 a-synuclein immunoreactive neurons were found in the cerebellum, hippocampus, thalamus, red nucleus, olfactory tubercle, cortex, SNpc and striatum of old mouse lemur primates ( Fig. 1J -L-N), whereas no immunostaining was detected in young animals ( Fig. 1I -K-M). Double immunofluorescence examination revealed that phosphor-Ser129 a-synuclein increases occurred within SNpc dopaminergic neurons in aged animals ( Fig. 2A) . Other post-translational modification may occur in a-synuclein concerns nitration. Midbrain sections from young and old animals were therefore stained with an anti-nitrated a-synuclein antibody to detect potential age-related modifications. Similar to the results with phosphorylated a-synuclein, immunoreactivity for nitrated a-synuclein was slightly increased within nigral neurons of aged animals (Fig. 2B) .
Brain sections were immunostained with antibody against Abamyloid as a control for proteinopathy. Ab deposits were observed in many brain regions, such as cortex, cerebellum, inferior and superior colliculi, and anterior olfactory nucleus (Fig. 1B) . Diffuse plaques were strongly positive for Ab-amyloid in the cortex of old animals ( Fig. 1P ) whereas no Ab deposits were found in young animals (Fig. 1O) . We did not observe bA4-amyloid immunostaining either in the SNpc or in the striatum whatever the age of the animals.
Discussion
The purpose of this study was to investigate age-related accumulation of a-synuclein. We found that it specifically occurs as mouse lemur primates aged, and within regions implicated in PD, such as the SNpc.
Diffuse extracellular cortical Ab-amyloid deposits were detected in every aged Microcebus brains, as previously reported by Bons and colleagues 9, 10 . Indeed, these histological changes consisted in a large number of senile plaques composed of degenerated neurites sometimes surrounding an amyloid plaque. In addition to the ''classic'' Ab-amyloid pathology, aging was also accompanied by the occurrence of a-synuclein in neurons of many brain areas and of interest in nigral cell bodies. Post-translational modifications of a-synuclein affect the biochemical and structural properties of the protein, and might promote aggregation and toxicity 15 . Phosphorylation at Ser129 has been reported to be the predominant modification of a-synuclein in Lewy bodies 16 . Of interest, immuno-expression of phosphoSer129 and nitrated a-synuclein confirmed the formation of phosphorylated and nitrated protein within dopaminergic neurons. Such striking relationship between aging and misfolded protein deposition in the brain of mouse lemur primates strongly suggests that this species carries a specific and unique potential for the further study of ecologically-occurring proteinopathies.
In conclusion, these data show for the first time that i) a-synuclein aggregation can occur spontaneously with aging in mouse lemur primates and that ii) Microcebus murinus may provide an ecological model for the study of age-associated synucleinopathy. This spontaneous animal model may provide an ideal system for understanding the mechanisms and the dynamic evolution of ageing and related proteinopathies as well as a model into which identifying predictive biomarkers and testing therapeutic interventions for AD and PD.
Methods
Animals. All mouse lemurs were housed in social cages with their mothers under controlled conditions of humidity, temperature, and light (12-h light/12-h dark cycle, lights on at 8.00 am); food and water were available ad libitum. Experiments were carried out in accordance with European Communities Council Directive of 3 June 2010 (2010/6106/EU) for care of laboratory animals in the breeding colony established at Brunoy (France, agreement A91.114.1) from a stock originally caught near the south coast of Madagascar, in 1965-1972. These studies were approved by the Ministry of Education and Science and the University of Bordeaux ethical committee. We studied 3 brains removed from young Microcebus murinus (2 males and 1 female) between 1.42 to 3.07 years old and 4 brains from old individuals (2 males and 2 females) aged 8.21 and 10.32 years old. All the animals were provided from the laboratory breeding colony at Brunoy (France, Perret M.).
Brain pathology. Neuropathological studies of mouse lemur brains were performed with procedures and antibodies used in human pathology, as described below.
Brains were fixed by immersion in 4% paraformaldehyde in 0.1 M Phosphate buffer (pH 7.4). One fixed hemi-brain was sectioned on a vibratome at 50mm on the sagittal plane. Immunohistochemistry was performed with a horseradish peroxydase (HRP) method with the following antibodies: anti a-synuclein clone LB509, a mouse monoclonal antibody (15100 dilution; Invitrogen, Cergy-Pontoise, France); anti PSer129, a mouse monoclonal antibody against phospho-Ser129 a-synuclein (15500; Wako); and anti Ab-amyloid clone 6F/3D, a mouse monoclonal antibody (15100; Dako, Trappes, France). Briefly, the sections were rinsed in PBS, permeabilized with PBS containing 0.3% triton X-100. For immunostaining with anti Ab-amyloid and anti PSer129, sections were pretreated with formic acid (80%) and next with proteinase K (Dako, Trappes, France) for Ab-amyloid immunolabelled sections only to enhance immunoreactivities. To block non specific reactions, sections were then exposed to a universal blocking reagent (Biogenex) for LB509 a-synuclein and PSer129 or to PBS containing 10% bovine albumin serum for 30 min for anti Abamyloid. Incubation with primary antibodies lasted overnight at 4uC. Subsequently, the sections were transferred in 3% H 2 O 2 in PBS for 15 min to inhibit endogenous peroxidases and treated with a ready-to-use goat anti mouse En Vision-HRP enzyme conjugate (Dako, Trappes, France) for 40 min. The highly sensitive diaminobenzidin plus (DAB1) and the 3-amino-9 ethyl carbazol plus (AEC1) (both from Dako, Trappes, France) were used as substrates chromogens. Finally, sections were counterstained with Mayer's hemalum and mounted in an aqueous medium for microscopy. Immunohistochemical negative controls were performed by omission of the primary antibody. Double immunofluorescence was performed with a mouse monoclonal phospho-Ser129 a -synuclein (15500; Wako) and a rabbit polyclonal anti tyrosine hydroxylase (TH) (154000; Millipore) as well as a mouse monoclonal nitrated a-synuclein (15100, clone Syn505; Invitrogen) and TH. For immunostaining with anti-nitrated a-synuclein, sections were pretreated 5 minutes with formic acid (80%). Secondary antibodies were Alexa Fluor 488-labeled goat anti-mouse (Invitrogen) for phospho-Ser129 a-synuclein or goat anti-mouse En Vision-HRP enzyme conjugate followed by a dylight-488 conjugated goat anti-horseradish peroxydase (Jackson ImmunoResearch Laboratories) for anti-nitrated a-synuclein. To localize TH in dopaminergic neurons, Alexa Fluor 568-labeled donkey anti-rabbit (Invitrogen) was used. 
